image
Healthcare - Medical - Devices - NYSE - US
$ 86.99
-0.685 %
$ 128 B
Market Cap
71.89
P/E
1. INTRINSIC VALUE

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems.[ Read More ]

The intrinsic value of one BSX stock under the base case scenario is HIDDEN Compared to the current market price of 87 USD, Boston Scientific Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BSX

image
FINANCIALS
14.2 B REVENUE
12.29%
2.34 B OPERATING INCOME
42.09%
1.59 B NET INCOME
128.08%
2.5 B OPERATING CASH FLOW
64.02%
-2.57 B INVESTING CASH FLOW
-28.00%
5 M FINANCING CASH FLOW
100.91%
4.21 B REVENUE
2.16%
733 M OPERATING INCOME
-1.87%
700 M NET INCOME
116.05%
-1.14 T OPERATING CASH FLOW
-140571.59%
-1.43 B INVESTING CASH FLOW
-426.57%
1.68 B FINANCING CASH FLOW
6891.67%
Balance Sheet Decomposition Boston Scientific Corporation
image
Current Assets 6.51 B
Cash & Short-Term Investments 865 M
Receivables 2.23 B
Other Current Assets 3.42 B
Non-Current Assets 28.6 B
Long-Term Investments 413 M
PP&E 3.3 B
Other Non-Current Assets 24.9 B
Current Liabilities 4.93 B
Accounts Payable 942 M
Short-Term Debt 531 M
Other Current Liabilities 3.46 B
Non-Current Liabilities 10.7 B
Long-Term Debt 8.96 B
Other Non-Current Liabilities 1.71 B
EFFICIENCY
Earnings Waterfall Boston Scientific Corporation
image
Revenue 14.2 B
Cost Of Revenue 4.34 B
Gross Profit 9.9 B
Operating Expenses 7.48 B
Operating Income 2.34 B
Other Expenses 751 M
Net Income 1.59 B
RATIOS
69.49% GROSS MARGIN
69.49%
16.45% OPERATING MARGIN
16.45%
11.19% NET MARGIN
11.19%
8.26% ROE
8.26%
4.53% ROA
4.53%
6.62% ROIC
6.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Boston Scientific Corporation
image
Net Income 1.59 B
Depreciation & Amortization 1.2 B
Capital Expenditures -800 M
Stock-Based Compensation 233 M
Change in Working Capital -770 M
Others 263 M
Free Cash Flow 1.7 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Boston Scientific Corporation
image
Wall Street analysts predict an average 1-year price target for BSX of $86.2 , with forecasts ranging from a low of $73 to a high of $100 .
BSX Lowest Price Target Wall Street Target
73 USD -16.08%
BSX Average Price Target Wall Street Target
86.2 USD -0.96%
BSX Highest Price Target Wall Street Target
100 USD 14.96%
4. DIVIDEND ANALYSIS
0.02% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Boston Scientific Corporation
image
Sold
0-3 MONTHS
58.7 M USD 5
3-6 MONTHS
18.4 M USD 5
6-9 MONTHS
9.54 M USD 8
9-12 MONTHS
9.62 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 week ago
Nov 08, 2024
Sell 2.68 M USD
Sorenson John Bradley
EVP, Global Operations
- 30580
87.6577 USD
1 week ago
Nov 05, 2024
Sell 221 K USD
Mahoney Michael F
Chairman, President & CEO
- 2596
85.1727 USD
1 week ago
Nov 05, 2024
Sell 13.6 M USD
Mahoney Michael F
Chairman, President & CEO
- 160182
84.7395 USD
2 weeks ago
Nov 01, 2024
Sell 589 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
84.33 USD
1 month ago
Oct 07, 2024
Sell 6.8 M USD
Mahoney Michael F
Chairman, President & CEO
- 80692
84.3127 USD
1 month ago
Oct 07, 2024
Sell 6.97 M USD
Mahoney Michael F
Chairman, President & CEO
- 82085
84.9416 USD
1 month ago
Oct 07, 2024
Sell 11.3 M USD
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
- 132527
85.0007 USD
1 month ago
Oct 01, 2024
Sell 586 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
83.86 USD
2 months ago
Sep 05, 2024
Sell 13.2 M USD
Mahoney Michael F
Chairman, President & CEO
- 162777
81.1696 USD
2 months ago
Sep 03, 2024
Sell 571 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
81.7 USD
2 months ago
Aug 28, 2024
Sell 1.13 M USD
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
- 14132
80 USD
2 months ago
Aug 26, 2024
Sell 1.11 M USD
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
- 14012
79.2546 USD
3 months ago
Aug 01, 2024
Sell 518 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
74.12 USD
4 months ago
Jul 01, 2024
Sell 540 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
77.3 USD
5 months ago
Jun 03, 2024
Sell 526 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
75.33 USD
5 months ago
May 29, 2024
Sell 4.79 M USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 63802
75.0987 USD
5 months ago
May 28, 2024
Sell 1.06 M USD
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
- 14011
75.3401 USD
5 months ago
May 22, 2024
Sell 4.89 M USD
Brennan Daniel J.
EVP and CFO
- 64454
75.9118 USD
5 months ago
May 23, 2024
Sell 3.58 M USD
Brennan Daniel J.
EVP and CFO
- 47621
75.1125 USD
5 months ago
May 21, 2024
Sell 1.36 M USD
Brown Vance R
SVP, GC and Corp. Secretary
- 18037
75.6005 USD
5 months ago
May 22, 2024
Sell 1.14 M USD
Brown Vance R
SVP, GC and Corp. Secretary
- 15006
76.0118 USD
6 months ago
May 10, 2024
Sell 959 K USD
Thepaut Eric Francis Yves
EVP & Pres, Eur, Mid-East, Afr
- 12931
74.141 USD
6 months ago
May 07, 2024
Sell 287 K USD
Dockendorff Charles J
Director
- 3946
72.7 USD
6 months ago
May 01, 2024
Sell 1.26 M USD
Sorenson John Bradley
EVP, Global Operations
- 17587
71.501 USD
6 months ago
May 01, 2024
Sell 499 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
71.47 USD
6 months ago
Apr 26, 2024
Sell 720 K USD
LUDWIG EDWARD J
Director
- 9818
73.2901 USD
7 months ago
Apr 01, 2024
Sell 1.13 M USD
Sorenson John Bradley
EVP, Global Operations
- 16351
69.2966 USD
7 months ago
Apr 01, 2024
Sell 478 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
68.42 USD
8 months ago
Mar 18, 2024
Sell 964 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 14506
66.4504 USD
8 months ago
Mar 01, 2024
Sell 463 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
66.35 USD
8 months ago
Feb 26, 2024
Sell 626 K USD
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
- 9335
67.07 USD
8 months ago
Feb 23, 2024
Sell 467 K USD
Carruthers Wendy
EVP, Human Resources
- 6983
66.89 USD
8 months ago
Feb 21, 2024
Sell 329 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 4960
66.35 USD
8 months ago
Feb 20, 2024
Sell 900 K USD
Brennan Daniel J.
EVP and CFO
- 13662
65.86 USD
9 months ago
Feb 13, 2024
Sell 455 K USD
LUDWIG EDWARD J
Director
- 7000
65.0319 USD
10 months ago
Jan 12, 2024
Sell 700 K USD
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
- 11660
60 USD
10 months ago
Jan 09, 2024
Sell 899 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 15172
59.25 USD
10 months ago
Jan 04, 2024
Sell 876 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 15000
58.4001 USD
10 months ago
Jan 03, 2024
Sell 690 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 11931
57.821 USD
10 months ago
Dec 29, 2023
Sell 4.71 M USD
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
- 81940
57.5 USD
11 months ago
Dec 15, 2023
Sell 649 K USD
Carruthers Wendy
EVP, Human Resources
- 11672
55.6096 USD
11 months ago
Dec 06, 2023
Sell 19.4 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 353
55.03 USD
11 months ago
Nov 20, 2023
Sell 448 K USD
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
- 8278
54.06 USD
1 year ago
Nov 15, 2023
Sell 632 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
54.1744 USD
1 year ago
Nov 06, 2023
Sell 5.95 M USD
Mahoney Michael F
Chairman, President & CEO
- 113356
52.507 USD
1 year ago
Oct 16, 2023
Sell 581 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
49.7869 USD
1 year ago
Oct 09, 2023
Sell 5.9 M USD
Mahoney Michael F
Chairman, President & CEO
- 113355
52.0884 USD
1 year ago
Sep 20, 2023
Sell 873 K USD
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
- 15867
55 USD
1 year ago
Sep 15, 2023
Sell 630 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
53.9537 USD
1 year ago
Sep 12, 2023
Sell 6.11 M USD
Mahoney Michael F
Chairman, President & CEO
- 113355
53.9054 USD
1 year ago
Aug 28, 2023
Sell 742 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 13971
53.14 USD
1 year ago
Aug 29, 2023
Sell 254 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 4657
54.5009 USD
1 year ago
Aug 25, 2023
Sell 796 K USD
Brown Vance R
SVP, GC and Corp. Secretary
- 15750
50.5242 USD
1 year ago
Aug 21, 2023
Sell 333 K USD
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
- 6600
50.4032 USD
1 year ago
Aug 18, 2023
Sell 867 K USD
Dockendorff Charles J
Director
- 17079
50.7425 USD
1 year ago
Aug 15, 2023
Sell 599 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
51.2962 USD
1 year ago
Jul 17, 2023
Sell 617 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
52.8467 USD
1 year ago
Jun 21, 2023
Sell 360 K USD
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
- 6697
53.7999 USD
1 year ago
Jun 15, 2023
Sell 621 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
53.2396 USD
1 year ago
May 16, 2023
Sell 3.39 M USD
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
- 63339
53.5982 USD
1 year ago
May 15, 2023
Sell 624 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
53.4944 USD
1 year ago
May 02, 2023
Sell 4.38 M USD
Thepaut Eric Francis Yves
EVP & Pres, Eur, Mid-East, Afr
- 83401
52.4879 USD
1 year ago
Apr 17, 2023
Sell 606 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
51.9598 USD
1 year ago
Apr 05, 2023
Sell 247 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 4903
50.4 USD
1 year ago
Mar 31, 2023
Sell 200 K USD
Sorenson John Bradley
EVP, Global Operations
- 4000
50 USD
1 year ago
Mar 31, 2023
Sell 250 K USD
Monson Jonathan
SVP, Global Controller and CAO
- 5000
50 USD
1 year ago
Mar 30, 2023
Sell 243 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 4903
49.6 USD
1 year ago
Mar 23, 2023
Sell 322 K USD
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
- 6703
47.97 USD
1 year ago
Mar 15, 2023
Sell 556 K USD
Carruthers Wendy
EVP, Human Resources
- 11671
47.603 USD
1 year ago
Mar 01, 2023
Sell 3.53 M USD
Brennan Daniel J.
EVP and CFO
- 75610
46.6385 USD
1 year ago
Mar 02, 2023
Sell 1.4 M USD
Brennan Daniel J.
EVP and CFO
- 30000
46.6638 USD
1 year ago
Mar 01, 2023
Sell 233 K USD
Monson Jonathan
SVP, Global Controller and CAO
- 5000
46.663 USD
1 year ago
Feb 21, 2023
Sell 107 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 2313
46.32 USD
1 year ago
Feb 22, 2023
Sell 154 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 3340
46.1 USD
1 year ago
Feb 17, 2023
Sell 95.5 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 2061
46.35 USD
1 year ago
Feb 16, 2023
Sell 65.9 K USD
Mirviss Jeffrey B.
EVP&Pres, Periph Intervent
- 1409
46.79 USD
7. News
Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript) Boston Scientific Corporation (NYSE:BSX ) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-Anello - VP & GM of Interventional Cardiology Conference Call Participants Danielle Antalffy - UBS Danielle Antalffy So good morning, everyone. Thanks so much for joining us. seekingalpha.com - 1 day ago
Boston Scientific Closes Acquisition of Axonics, Inc. MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. prnewswire.com - 1 day ago
Kidney Stone Management Market Forecast Report, 2024-2032 - Cook Group, Richard Wolf, Boston Scientific, and Dornier MedTech Actively Engaged in M&As to Increase Share Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global market size for kidney stone management reached a value of USD 1.80 billion in 2023. The market is expected to grow at a CAGR of 5.20% between 2024-2032 and attain a value of USD 2.84 billion by 2032. globenewswire.com - 1 week ago
Boston Scientific to Participate in the 2024 UBS Global Healthcare Conference MARLBOROUGH, Mass. , Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024. prnewswire.com - 1 week ago
Boston Scientific Announces Agreement to Acquire Cortex, Inc. Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass. , Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. prnewswire.com - 1 week ago
Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript Boston Scientific Corporation (NYSE:BSX ) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph Fitzgerald - Executive Vice President and Group President, Cardiology Lance Bates - Senior Vice President and President Janar Sathananthan - Chief Medical Officer Kenneth Stein - Chief Medical Officer Conference Call Participants Operator Good day, and welcome to the Boston Scientific Cardiology Business Update. [Operator Instructions] Please note, this event is being recorded. seekingalpha.com - 2 weeks ago
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2 weeks ago
Boston Scientific Stock Gains From Market Expansion, Innovation BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options. zacks.com - 2 weeks ago
The Zacks Analyst Blog The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific are included in this Analyst Blog. zacks.com - 2 weeks ago
Why The Fundamentals Make Me Bullish On Boston Scientific Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more. While all other Seeking Alpha analysts have rated it a Hold this year, I have a Buy rating and expect the price to grow nearly 15% in the coming year. seekingalpha.com - 2 weeks ago
Looking for a Growth Stock? 3 Reasons Why Boston Scientific (BSX) is a Solid Choice Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market. zacks.com - 2 weeks ago
Buy 5 S&P 500 Stocks to Tap Potential Short-Term Price Appreciation These five stocks have provided double-digit returns year to date. Despite the rally, these stocks have double-digit upside potential for the short term. zacks.com - 2 weeks ago
8. Profile Summary

Boston Scientific Corporation BSX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 128 B
Dividend Yield 0.02%
Description Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Contact 300 Boston Scientific Way, Marlborough, MA, 01752-1234 https://www.bostonscientific.com
IPO Date May 19, 1992
Employees 48000
Officers Mr. Michael F. Mahoney Chairman, President & Chief Executive Officer Ms. Jodi Euerle Eddy Senior Vice President and Chief Information & Digital Officer Mr. Jonathan R Monson Senior Vice President of Investor Relations Ms. Emily Woodworth Senior Vice President, Global Controller & Chief Accounting Officer Mr. Jeffrey B. Mirviss M.B.A. Executive Vice President & President of Peripheral Interventions Mr. Vance R. Brown Senior Vice President, General Counsel & Corporate Secretary Ms. Mary Beth Moynihan Senior Vice President of Market Access & Chief Marketing Officer Mr. Arthur Crosswell Butcher Executive Vice President and Group President of MedSurg & Asia Pacific Mr. Joseph M. Fitzgerald Executive Vice President & Group President of Cardiology Mr. John Bradley Sorenson Executive Vice President of Global Operations